TYRA (Tyra Biosciences) Marketable Securities: $298.51 Mil (As of Mar. 2026)


TYRA Tyra Biosciences Inc TYRA
28 GF Score
Price $30.86
! 2 Warning Signs
View Full Analysis

What is Tyra Biosciences Marketable Securities?

Tyra Biosciences TYRA +0.78% 28 Marketable Securities is $298.51 Mil as of Mar. 2026. GuruFocus rates TYRA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Tyra Biosciences's Marketable Securities for the quarter that ended in Mar. 2026 was $298.51 Mil.

Tyra Biosciences's annual Marketable Securities increased from Dec. 2023 ($145.46 Mil) to Dec. 2024 ($249.48 Mil) but then declined from Dec. 2024 ($249.48 Mil) to Dec. 2025 ($178.62 Mil).

Tyra Biosciences  (NAS:TYRA) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Tyra Biosciences Marketable Securities Related Terms

Tyra Biosciences Marketable Securities Historical Data

* Premium members only.

The historical data trend for Tyra Biosciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tyra Biosciences Marketable Securities Chart

Tyra Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 145.46 249.48 178.62

Tyra Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 218.22 197.78 212.97 178.62 298.51
TYRA
28GF Score
Tyra Biosciences Inc TYRA
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tyra Biosciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $298.51 Mil mean?
Tyra Biosciences (TYRA) has a Marketable Securities of $298.51 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Tyra Biosciences and its competitors.
Is Tyra Biosciences' Marketable Securities too high?
Tyra Biosciences' current Marketable Securities is $298.51 Mil. Overall, Tyra Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Tyra Biosciences' Marketable Securities compare to SION and IOVA?
Tyra Biosciences' Marketable Securities of $298.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Tyra Biosciences and its competitors. Tyra Biosciences's current Marketable Securities is $298.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tyra Biosciences stock overvalued right now?
Tyra Biosciences (TYRA) has a current Marketable Securities of $298.51 Mil. The current Marketable Securities is $298.51 Mil. Tyra Biosciences' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Tyra Biosciences (TYRA), the current Marketable Securities is $298.51 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tyra Biosciences Business Description

Address 2656 State Street, Carlsbad, CA, USA, 92008
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
28GF Score

Get the complete analysis for TYRA

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.86
Price